Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2017-11-14 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Pre-quotation Disclosure 4 pages 451.9KB
Capital/Financing Update Classification · 95% confidence The document is a pre-quotation disclosure related to the initial public offering (IPO) of Telix Pharmaceuticals Limited shares on the Australian Securities Exchange (ASX). It details the allocation of shares, escrow arrangements, commencement of trading, and use of funds from the offer. It also lists enclosed documents such as the prospectus, constitution, audited accounts, and governance documents. The content focuses on capital raising and share issuance information rather than financial results or management commentary. Therefore, this document is best classified as a Capital/Financing Update (CAP) since it provides detailed information about the company's fundraising and share allocation in connection with the IPO.
2017-11-14 English
Top 20 Holders 2 pages 13.3KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'FIRST 20 INVESTORS REPORT' and lists the top 20 shareholders of Telix Pharmaceuticals Limited with their shareholdings and percentage of issued capital. It is a snapshot of major shareholders rather than a full financial report or announcement of a meeting or vote. The document length is short (2360 characters) and it does not contain financial statements, management discussion, or regulatory certifications. It is a typical major shareholding notification showing significant ownership stakes. Therefore, the most appropriate classification is 'Major Shareholding Notification' (MRQ).
2017-11-14 English
Information Form and Checklist 15 pages 362.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX Information Form and Checklist related to the application for admission to the official list of ASX Limited. It contains detailed corporate, management, auditor, registry, and compliance information required for listing on the ASX. It is not a financial report, earnings release, or any other type of periodic report. It is also not a simple announcement but a comprehensive form supporting the listing application. This type of document is regulatory in nature and does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is best classified under Regulatory Filings (RNS) as it is a compliance and regulatory submission to the ASX for listing purposes.
2017-11-14 English
Constitution 54 pages 504.6KB
Governance Information Classification · 100% confidence The document is titled 'Constitution' and contains detailed sections on company governance, share capital, meetings, directors, executive officers, indemnity, and other corporate governance matters. It is a comprehensive internal governance document outlining the rules and procedures for the company, including definitions, powers, meetings, and director roles. There is no indication of financial data, audit results, earnings, or regulatory filings. The content aligns with a governance document rather than a financial report or announcement. Therefore, the document best fits the category of Governance Information (CGR).
2017-11-14 English
Audited Accounts for period ended 30 June 2017 29 pages 1.6MB
Regulatory Filings
2017-11-14 English
Therapeia GmbH & Co.KG Audited Accounts 2016 and 2015 24 pages 5.6MB
Regulatory Filings
2017-11-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.